ArticleThe Pediatric infectious disease journal2017
Effectiveness of Palivizumab in High-risk Infants and Children: A Propensity Score Weighted Regression Analysis.
Article in The Pediatric infectious disease journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 87 citations in OpenAlex.
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.The Cochrane database of systematic reviews · 2025Pooled it
- Palivizumab for preventing severe respiratory syncytial virus (RSV) infection in children.The Cochrane database of systematic reviews · 2021Pooled it
- Systematic Review: Efficacy, Safety Profile, and Cost-Effectiveness of Nirsevimab Versus Palivizumab for RSV Prevention in Children Under 24 Months.Children (Basel, Switzerland) · 2026Review
- Eliminating interactions with the viral Fc receptor improves antibody-mediated protection against neonatal HSV infection in mice.Science translational medicine · 2025Article
- Beyond the first breath: comprehensive respiratory syncytial virus prevention through maternal immunization and infant immunoprophylaxis.Asian biomedicine : research, reviews and news · 2025Review
- RSV: an update on prevention and management.Australian prescriber · 2025Review
- Inpatient service utilization amongst infants diagnosed with Respiratory Syncytial Virus infection (RSV) in the United States.PloS one · 2025Observational
- A Statistical Model to Predict Protection Against Infant Respiratory Syncytial Virus Disease Through Maternal Immunization.Vaccines · 2024Article
- [Expert recommendations for the prevention of common respiratory viral infections in neonates].Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics · 2024Article
- Article
- Development of an Antiviral Ion-Activated In Situ Gel Containing 18β-Glycyrrhetinic Acid: A Promising Alternative against Respiratory Syncytial Virus.Pharmaceutics · 2023Article
- The Quest for a Respiratory Syncytial Virus Vaccine for Older Adults: Thinking beyond the F Protein.Vaccines · 2023Review
- Burden of Respiratory Syncytial Virus Related Acute Lower Respiratory Tract Infection in Hospitalized Thai Children: A 6-Year National Data Analysis.Children (Basel, Switzerland) · 2022Article
- Alternative Routes of Administration for Therapeutic Antibodies-State of the Art.Antibodies (Basel, Switzerland) · 2022Review
- Clinical manifestations and outcome of viral acute lower respiratory infection in hospitalised children in Myanmar.BMC infectious diseases · 2022Article
- An outbreak of RSV infections in a neonatology clinic during the RSV-season.BMC pediatrics · 2021Article
- Observational
- Considerations for a Respiratory Syncytial Virus Vaccine Targeting an Elderly Population.Vaccines · 2021Review
- Effectiveness of palivizumab in preventing respiratory syncytial virus infection in high-risk children.Human vaccines & immunotherapeutics · 2021Article
- Sendai Virus-Vectored Vaccines That Express Envelope Glycoproteins of Respiratory Viruses.Viruses · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 5 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundInfants with premature birth ≤35 weeks gestational age, chronic lung disease of prematurity and congenital heart disease are at an increased risk for lower respiratory tract infections and hospitalization from respiratory syncytial virus (RSV), which has been shown in randomized trials to be prevented by palivizumab. However, palivizumab effectiveness (PE) has not been studied in a large clinical setting.
methodsA multicenter study among high-risk US and Canadian children younger than 24 months hospitalized with lower respiratory tract infection and whose nasopharyngeal aspirates were tested for human metapneumovirus (HMPV) and RSV were the subjects of the trial. We conducted a test-negative case-control study in these subjects to determine PE. We used an inverse propensity score weighted (IPSW) multiple logistic regression model to adjust PE.
resultsPalivizumab was used in 434 (51%) of 849 eligible children. RSV was identified in 403 (47%) children. The unadjusted PE was 43% [95% confidence interval (CI), 34%-51%)]. After IPSW adjustment, the adjusted PE was 58% (95% CI, 43%-69%). Palivizumab prevented intensive care unit admissions (PE, 62%; 95% CI, 35%-78%). PE for 29-35 weeks gestational age and ≤6 months of chronologic age without chronic lung disease of prematurity or congenital heart disease was 74% (95% CI, 56%-85%).
conclusionsUsing a test-negative case-control design with RSV molecular detection, palivizumab is shown to prevent RSV hospitalizations and intensive care unit admissions in high-risk infants.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.